SCHEMBL9956086

SCHEMBL9956086

Cc1cc(C)cc(-n2cc(C(=O)O)cn2)c1

nearest known ligand 0.62

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALKBH2 Q6NS38 2/20 0.62
HPGDS O60760 1/20 0.62
ALKBH1 Q13686 1/20 0.56
EGLN1 Q9GZT9 5/20 0.49
TPMT P51580 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5067030 0.92 ALKBH2 (0.54) ALKBH2HPGDSALKBH1EGLN1TPMT
SCHEMBL5746807 0.86 MAPT (0.45) ALKBH2HPGDSALKBH1EGLN1MAPT
SCHEMBL29544523 0.84 ALKBH2 (0.69) ALKBH2HPGDSEGLN1MAPTHPGD
SCHEMBL2854056 0.84 ALKBH2 (0.69) ALKBH2HPGDSEGLN1MAPTHPGD
SCHEMBL20462879 0.83 KAT6A (0.50) ALKBH2HPGDSALKBH1TPMTMAPT
SCHEMBL27575419 0.83 ALKBH2 (0.77) ALKBH2HPGDSALKBH1EGLN1MAPT
SCHEMBL2852078 0.83 ALKBH2 (0.72) ALKBH2HPGDSEGLN1MAPTHPGD
SCHEMBL15153223 0.82 ATM (0.46) ALKBH2HPGDSALKBH1MAPTHPGD
SCHEMBL17844065 0.81 ALKBH2 (0.51) ALKBH2HPGDSALKBH1EGLN1TPMT
SCHEMBL20462881 0.80 KAT6A (0.60) ALKBH2HPGDSALKBH1EGLN1TPMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103237800-B Amide derivatives and use thereof MITSUBISHI TANABE PHARMA CORP. (JP) 2015-10-21 CN disclosed
US-9150555-B2 Amide derivative and use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-10-06 US disclosed
US-9150555-B2 Amide derivative and use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-10-06 US disclosed
US-9150555-B2 Amide derivative and use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-10-06 US disclosed
EP-2655323-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2013-10-30 EP disclosed
EP-2657230-A1 AMIDE DERIVATIVE AND USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2013-10-30 EP disclosed
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-15 US disclosed
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-15 US disclosed
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-15 US disclosed
CN-103237800-A Amide derivatives and use thereof MITSUBISHI TANABE PHARMA CORP 2013-08-07 CN disclosed
WO-2012083953-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO PHARMA A/S (DK) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF IL2, IL4, IL5 ALKBH2 3345/4885HPGDS 167/4885ALKBH1 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.